Carregant...
人源化BCMA CAR-T细胞挽救治疗鼠源BCMA CAR-T细胞治疗后再进展的难治多发性骨髓瘤二例
OBJECTIVE: To observe the efficacy and safety of humanized anti-BCMA chimeric antigen receptor modified（BCMA CAR）-T cell therapy after disease progression with their murine BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma （MM）. METHODS: Study participants underwent leuka...
Guardat en:
| Publicat a: | Zhonghua Xue Ye Xue Za Zhi |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Editorial office of Chinese Journal of Hematology
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8295619/ https://ncbi.nlm.nih.gov/pubmed/34384157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.06.010 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|